REGN REGENERON PHARMACEUTICALS, INC.

Price Chart

Executive Summary

BofA Securities double-upgraded Regeneron Pharmaceuticals (REGN) to Buy from Underperform on Jan 7, raising its price target to $860 from $627 — a 37% increase and a 22% upside from the current $707.06. The call is part of a 12-firm cluster of analyst actions on the same day, though no other ratings changes were disclosed. BofA has a decent track record: 54% accuracy on 3,282 calls with a 5.1% average return, near the middle of the 15 covering firms. The Street consensus is heavily bullish: 30 of 38 analysts rate Buy or Strong Buy, 8 at Hold, and none bearish. The mean price target is $877.73, with a high of $1,057 and a low of $730. BofA’s $860 target sits below the mean but still implies meaningful upside. EPS revisions over the last 30 days have skewed positive: 8 up vs 6 down for the current quarter and 9 up vs 8 down for the full year. Insider selling persists (five recent trades, all sells), while institutional flows are mixed — a large new position from Norges Bank and a doubling from a Renaissance fund offset trims from Two Sigma and another Renaissance fund. The upgrade reinforces the bullish consensus but lacks a near-term catalyst (next earnings July 30, >30 days away). Traders should view this as a firm conviction upgrade from a previously bearish house, adding weight to the long thesis but tempered by insider exits.

Impact Score

Consensus & Targets

The analyst consensus is overwhelmingly bullish: 11 Strong Buy, 19 Buy, 8 Hold, 0 Sell, 0 Strong Sell, based on 38 analysts. Three-quarters of the Street is at Buy or Strong Buy, with no bearish ratings. BofA’s upgrade aligns with the consensus direction but is notable because it came from a previously bearish house (Underperform).

Current price: $707.06. Mean target: $877.73, median: $882.50, high: $1,057, low: $730 (28 analysts). Implied upside to mean: +24%. BofA’s $860 target is 2% below the mean but still 22% above the current price, and well above the low target of $730. The firm sits just below the consensus median.

Recent Analyst Activity

No upgrades or downgrades in the last 30 days (0 up, 0 down). However, EPS estimates are trending upward: over the past 30 days, the current quarter saw 8 upward revisions vs 6 down, the next quarter 8 up vs 5 down, and the current fiscal year 9 up vs 8 down. Net revisions are positive, supporting a favorable near-term earnings outlook.

Firm Track Record — B of A Securities

B of A Securities accuracy: 54% on 3282 calls | avg return: 5.1%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

BofA Securities has a 54% accuracy rate on 3,282 analyst calls with a 5.1% average return — about median among REGN’s covering firms. The best performers by accuracy (small sample) are UBS (67% on 6 calls) and Canaccord Genuity (57% on 7 calls, 9.4% avg return). The worst performers by accuracy: Wells Fargo (33% on 9), JP Morgan (33% on 6), and RBC Capital (33% on 18). BofA’s return is slightly above the average of covering firms, lending moderate credibility to the upgrade.

Earnings Estimates

Next earnings: Jul 30, 2026

Cross-Platform Signals

Insider trading: Five recent sells by executives (Arthur Ryan, Huda Zoghbi, Jason Pitofsky) totaling ~$60k, all in the last 90 days — a bearish signal. Congressional activity: one small buy ($1k–$15k) by Rep. Julia Letlow (R-LA). Institutional flows: mixed — Two Sigma trimmed 40%, one Renaissance fund near-exited (-96.7%), but Sound Shore added 52.9%, Norges Bank opened a new $1B position, and another Renaissance fund doubled (+510.6%). Short interest is not reported. The analyst upgrade (bullish) diverges from insider selling but converges with positive institutional additions and earnings revisions.

Documents Analyzed

Report based on filing metadata.

US Market Status